{"eventGroups":[{"deathsNumAffected":28,"deathsNumAtRisk":198,"description":"500 mg/m\\^2 pemetrexed, IV infusion\n\nPemetrexed: Alvopem® was administered every 3 weeks with a dose of 500 mg/m\\^2","id":"EG000","otherNumAffected":190,"otherNumAtRisk":198,"seriousNumAffected":50,"seriousNumAtRisk":198,"title":"NanoAlvand Pemetrexed"}],"frequencyThreshold":"0","otherEvents":[{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 4.0 Beta","stats":[{"groupId":"EG000","numAffected":177,"numAtRisk":198}],"term":"Anaemia"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 4.0 Beta","stats":[{"groupId":"EG000","numAffected":49,"numAtRisk":198}],"term":"leukopenia"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 4.0 Beta","stats":[{"groupId":"EG000","numAffected":57,"numAtRisk":198}],"term":"neutropenia"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 4.0 Beta","stats":[{"groupId":"EG000","numAffected":20,"numAtRisk":198}],"term":"Thrombocytopenia"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Investigations","sourceVocabulary":"MedDRA 4.0 Beta","stats":[{"groupId":"EG000","numAffected":20,"numAtRisk":198}],"term":"Alanine aminotransferase increased"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Investigations","sourceVocabulary":"MedDRA 4.0 Beta","stats":[{"groupId":"EG000","numAffected":12,"numAtRisk":198}],"term":"Aspartate aminotransferase increased"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Investigations","sourceVocabulary":"MedDRA 4.0 Beta","stats":[{"groupId":"EG000","numAffected":48,"numAtRisk":198}],"term":"Creatinine renal clearance decreased"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 4.0 Beta","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":198}],"term":"Renal disorder"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"General disorders","sourceVocabulary":"MedDRA 4.0 Beta","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":198}],"term":"Drug intolerance"}],"seriousEvents":[{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 4.0 Beta","stats":[{"groupId":"EG000","numAffected":50,"numAtRisk":198}],"term":"Anaemia"}],"timeFrame":"Three years and half"}